Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from NewcelX ( (NCEL) ).
On January 12, 2026, NewcelX Ltd. reported peer-reviewed positive results from an international collaborative study published in Diabetology, showing that engineered scaffolds incorporating extracellular matrix from decellularized human pancreas can support the function of encapsulated pluripotent stem cell–derived islets for Type 1 Diabetes treatment within a removable delivery system. The findings, generated with academic partners in Australia and the United States and backed by funding from diabetes-focused foundations, indicate that biomaterial design and tissue microenvironment are critical for sustaining islet function and may enable safer, retrievable cell-therapy delivery without chronic immune suppression, reinforcing the scientific rationale behind NewcelX’s IsletRx program and underlining the company’s strategic emphasis on advancing cell-based therapies toward clinical trials in Type 1 Diabetes.
More about NewcelX
NewcelX Ltd. (Nasdaq: NCEL) is a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, with a primary therapeutic focus on Type 1 Diabetes and additional programs in Amyotrophic Lateral Sclerosis (ALS). The company’s platform integrates advanced stem-cell technologies, biomaterials and neuroscience expertise to create scalable regenerative medicine solutions, including its investigational stem cell–derived islet therapy IsletRx, and it operates from headquarters in Zurich, Switzerland with R&D facilities in Ness Ziona, Israel.
Average Trading Volume: 206,969
Technical Sentiment Signal: Sell
Current Market Cap: $10.07M
Find detailed analytics on NCEL stock on TipRanks’ Stock Analysis page.